Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

Laborie Medical Technologies Acquires Pelvalon

Laborie Medical Technologies Corp. (Laborie) a specialist medical technology company, announced today that it has acquired Pelvalon, Inc., a privately held medical device company located in Redwood City, CA.

Pelvalon has developed an innovative product called the Eclipse™ System, a non-surgical, patient-controlled device for women suffering from fecal incontinence (FI). FI is a pelvic floor disorder that affects one in ten women. The Eclipse has a compelling clinical profile validated in multiple studies, is FDA-cleared and has established reimbursement. The product is simple, safe and effective and its reputation has spurred demand from numerous healthcare professionals and patients across the country.

“Laborie’s mission every day is to operate as a world-class specialist medical company making and advancing technologies that preserve and restore human dignity,” said Michael Frazzette, President & CEO of Laborie. “Our mission is well served by the addition of Eclipse™ to help patients who suffer from this difficult condition.”

“I am grateful for the dedicated work of my colleagues to bring the therapy to this point, and we are delighted that Laborie will be able to scale and deliver Eclipse™ to the doctors and patients who need it,” said Miles Rosen, Pelvalon Founder and CEO. “Laborie’s mission aligns perfectly with this technology.”

“Patricia Industries is committed to supporting Laborie in its mission to provide patients and healthcare professionals with innovative and effective therapeutic and diagnostic technologies that preserve and restore human dignity,” said Yuriy Prilutskiy, Head of Patricia Industries North America, a part of Investor AB, and owner of Laborie. “This acquisition further supports Laborie’s long-term growth, leverages Patricia Industries’ healthcare and life sciences expertise and aligns with our organization’s purpose of creating value for people and society by building strong and sustainable businesses.”

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Akura Medical, a Shifamed Portfolio Company, Closes $35M in Series B Financing

Akura Medical reports the funds will be used to apply for FDA 510(k) clearance for the Akura Mechanical Thrombectomy Platform, support clinical trials for additional indications, and scale manufacturing capabilities.

Laverock Therapeutics Raises £13.5M

Laverock Therapeutics notes the funding will enable further development of the GEiGS technology and progression of Laverock’s programs in regenerative medicine and immuno-oncology, with a focus on Type I Diabetes and solid tumor responsive T-cell and macrophage-based immune therapies, through to in vitro and in vivo validation.

SpineX Receives NIH SBIR Phase II Award for SCiP Clinical Trial in Children With CP

These funds will go towards completing a pivotal clinical trial to test the efficacy and safety of our proprietary SCiP™ device in children living with Cerebral Palsy (CP) notes SpineX.

Summus Raises $19.5 Million

Fundraise supports market expansion with Summus emerging as the premier clinical platform to share and access high quality specialty expertise across the continuum of care — serving employers, payers, health systems and physician groups.

Thirona Raises €7,5 Million New Financing to Accelerate the Adoption of its Breakthrough Innovations for Precision Medicine

With this financing, Thirona plans to accelerate the adoption of its break-through innovations for precision medicine.

By using this website you agree to accept Medical Device News Magazine Privacy Policy